Robin Carhart-Harris

Forgiveness might be too much to say that, but an understanding of sort of the pathetic, weak side.

nature of the abuser and how they could have done something like this.

And it was a breakthrough at the time.

There was a lot of tears.

There were, you know, wet eyes with everyone in the room, really.

And yeah, it was considered very beneficial to the patient to go through that experience.

Yeah.

I mean, so you're painting a picture of obviously the other side of this therapy question, which is, I mean, it has to be tremendously rewarding to be a therapist under these conditions where you're seeing people basically do decades worth of psychological work over the course of hours.

I mean, this is not the normal experience of talk therapy where you can

have a conversation with someone for 20 years and basically you're talking to the same person 20 years later, it has to be very rewarding and in success.

What do we know about people for whom psychedelics hold obvious therapeutic promise and people who should stay away?

I mean, what are the exclusion criteria and contraindications you're working with in research and

What do you think is just a ground truth insofar as we understand it for people out there in the public who probably shouldn't take any of these drugs?

You might want to differentiate the various classes of drugs or specific compounds with respect to risk, but what's your view of who benefits and who is courting obvious harm?

Sure.

Yeah.

Well, I can respond to that empirically.

While it's true that most of the studies that have been done are small, there are a lot of studies now.

And I didn't speak to the reliability in terms of the clinical benefits, because the results are very reliable.

They've been very well replicated, positive results, almost without exception.